CNBC Changemakers and Power Players Podcast: Gilead Sciences Chief Commercial & Corporate Affairs Officer and 2026 CNBC Changemaker Johanna Mercier on ending HIV epidemic, life hacks, and ...
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: CNBC
spoke with Johanna Mercier, Chief Commercial & Corporate Affairs Officer at Gilead Sciences and a 2026 CNBC Changemaker. Mercier discusses Gilead's groundbreaking HIV prevention innovation (a twice-yearly injection with 99.9% efficacy) and how her team moved within months of U.S. approval to expand access across Sub-Saharan Africa, where the need is greatest. She shares why impact (not title) drives her leadership, how personal loss reshaped her sense of purpose, and what it takes to lead through global health crises. Listen to the full episode here . New episodes drop every Tuesday. All references must be sourced to CNBC Changemakers and Power Players podcast. MERCIER ON ENDING HIV EPIDEMIC JULIA BOORSTIN: Tell us about your work over the past couple of years, expanding access to HIV prevention and why this is so important to you. JOHANNA MERCIER: Oh, absolutely. It's a pleasure to talk about this. I work at Gilead Sciences. It's a company that's been focused on HIV for t
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences (GILD) had its price target raised by Daiwa Securities Group Inc. from $129.00 to $161.00. They now have an "outperform" rating on the stock.MarketBeat
- Gilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy [Yahoo! Finance]Yahoo! Finance
- Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral TherapyBusiness Wire
- 2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 2/10/26 - Beat
GILD
Sec Filings
- 2/24/26 - Form 10-K
- 2/23/26 - Form 8-K
- 2/18/26 - Form 4
- GILD's page on the SEC website